ADG-2

Invivyd's CANOPY Phase 3 trial demonstrated that PEMGARDA (pemivibart) achieved an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months (nominal p <0.0001).

Invivyd has signed a $30 million term loan facility with Silicon Valley Bank, providing non-dilutive capital access contingent on meeting specific milestones and conditions.

Invivyd's VYD2311 demonstrates positive safety and pharmacokinetic profiles in an ongoing Phase 1/2 clinical trial, with complete enrollment and dosing.

The FDA updated the PEMGARDA™ EUA Fact Sheet to reflect accurate in vitro neutralization activity against dominant circulating variants KP.3.1.1 and LB.1.

The FDA authorized pemivibart for preexposure prophylaxis of COVID-19 in moderately to severely immunocompromised individuals aged 12 years and older.